Chen, Chun-Hsien <br/><br/>
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.  [electronic resource] 

 -  Scientific reports  05 2019 
 - 7086 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-019-43554-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Aged<br/>Anilides--adverse effects<br/>Antiviral Agents--therapeutic use<br/>Carbamates--adverse effects<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--complications<br/>Macrocyclic Compounds--adverse effects<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Retrospective Studies<br/>Ribavirin--adverse effects<br/>Ritonavir--adverse effects<br/>Sulfonamides--adverse effects<br/>Sustained Virologic Response<br/>Uracil--adverse effects<br/>Valine